Phase 3 SPARTAN data served as basis for approval, which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.

A Statement from the National Kidney Foundation (NKF)

New findings from an international research team led by psychiatrists at NYU School of Medicine show that a newly-developed analytic model can predict soon after a shocking or scary event – and with significant accuracy -- the likelihood of someone developing Post-Traumatic Stress Disorder (PTSD).

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations.

Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, announced the closing of a $65 million Series B financing. Proceeds will be used to advance lead programs from the company’s growing pipeline into clinical testing, including small molecule monoPARP inhibitors.

Risk greatest in people with later-stage cancers and lung and colon cancers

JHL Biotech announced that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL).

MetTel is helping Rotech Healthcare Inc. to drive better patient care and personalization at healthcare facilities and at home through an innovative mobile initiative that has raised Rotech’s workforce productivity and doubled customer contact, both companies announced.

Nautilus Medical has announced delivery of their robust image management platform with all features to any medical professionals and students at no cost.

To Meet Burgeoning Need, RCA Adds a Third Center in New Jersey for Life-Saving Addiction Treatment Services

Leading Provider of Post-Acute Care Forms Component Patient Safety Organization

Updated Phase 3 ALCYONE results, featured as oral presentation at ASH 2018, show improved progression-free survival in newly diagnosed patients

Novartis announced longer-term analyses of both ELIANA and JULIET, the pivotal clinical trials of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL), respectively.

OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-888 for the treatment of Pancreatic Cancer. OBI-888 is a first in class monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Patients at Hunt Regional Medical Center in Greenville, Texas can now access industry leading interactive features on their patient-room televisions, thanks to the hospital’s launch this month of Allen Technologies’ E3 Patient Engagement Solution.

American Academy of Orthopaedic Surgeons issued the following announcement on Nov. 16.A new review article published in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) finds arthroscopic (joint replacement or reconstruction) management could be a promising option for young, active patients diagnosed with GHOA.

Pioneers in reproductive medicine to recruit patients for clinical trial of new method of testing embryos for chromosome abnormalities

Guidelines focus on lifestyle and behavioral management, pharmacologic approaches, and strategies for avoiding and treating diabetes-related complications